The People Behind Your Project

Travis is responsible for business development, corporate strategy, and companywide project management. Prior to joining American Injectables, he held roles of increasing responsibility in operations and business development at Actavent Pharmaceuticals along with experience in 503B outsourcing for hospital markets. Previously, he worked at the biotechnology firm Amgen in Scientific Affairs. Mr. Allen received his Pharm.D. from the University of Florida.

Ben brings more than 40+ years of hands-on operational and quality expertise with sterile drug manufacturing on a global level. He specialized in new plant startups, site quality remediations, lean transformations, technology/product transfers, integration of operations and quality units, and building effective organizational structure during his career at Bayer Healthcare, Boehringer Ingelheim, Teva, AMRI, and private Pharma. Ben focuses on building, leading, and developing high-performance teams that demonstrate respect, trust, integrity, and accountability.

Yoarrys Rivera joined American Injectables in August 2021. Yoarrys has over 20 years of experience in the pharmaceutical industry with an established career in Quality Assurance at organizations such as Pfizer, Inc., Abbott Diagnostics, Ltd., and Capsugel. She is responsible for Quality Assurance and Compliance, providing GMP oversight and guidance to support manufacturing, commissioning, qualification, and product transfer and managing the Quality Management System to industry standards and regulatory requirements.

Brittany has joined American Injectables as the Senior Vice President of Business Development. She brings with her more than 16 years of specialized expertise in the pharmaceutical Contract Development and Manufacturing sector. She previously held Business Development leadership roles at Curia Global, Inc., Nitto Avecia Pharma Services, and NovaCina where she demonstrated her ability to grow and foster sales teams and processes while exceeding revenue targets. Her deep industry insights and sales leadership are poised to propel the company toward achieving its sales and revenue objectives.

As Chairman of the Board, Subhanu Saxena joins American Injectables from New Rhein Healthcare Investors. At New Rhein, he has served as a Managing Partner since 2017. Subhanu is an accomplished executive with experience in Europe, North America, Africa, and Asia, and has worked in pharmaceuticals, fast-moving consumer goods (FMCG), consulting, and banking. Prior to joining New Rhein, Subhanu was the Managing Director & Global Chief Executive Officer of Cipla, a global pharmaceutical manufacturing company with a presence in over 170 countries from 2013 to 2016. Prior to Cipla, from 2009 to 2012 Subhanu served as a Pharma Executive Committee Member for Novartis Pharmaceuticals responsible for Global Product Strategy and Commercialization, having previously been Country President and Pharma CEO of Novartis UK and Ireland from 2005 to 2009. In 2016, he was awarded a Finance Monthly “CEO of the Year” award for India-based CEOs. Subhanu has an MBA from INSEAD and an MA (with Honors) in Engineering Science from Oxford University. He speaks six languages, loves loud music, plays guitar, and is a lecturer and teacher of Sanskrit and Vedan.

Greg Parekh led the investment into American Injectables and serves as a Board member. Greg founded New Rhein Healthcare Investors in 2010 and is a Managing Partner. Before launching New Rhein, Greg led the integration planning for Alcon on behalf of Novartis AG, where he previously ran the Mergers & Acquisitions group from 2004 to 2009. During his time at Novartis, Greg helped execute over 20 transactions with a total deal value of more than $70 billion. Prior to joining Novartis, Greg headed Deutsche Bank’s European Healthcare Group from 1998 to 2004. Greg joined Deutsche Bank from Bear Stearns in New York, where he started his career in 1995 as an associate in the Life Sciences group. Greg has served as a director of the companies in which New Rhein made its initial deal-by-deal investments, Novagali Pharma, SA (ophthalmology), Chase Pharmaceuticals (Alzheimer’s), and Biocartis BV (oncology diagnostics), for which Greg also served as Chief Executive Officer from 2011 to 2013. Greg presently serves on the boards of New Rhein Fund 18 portfolio companies, Softhale NV and Neuraptive Therapeutics, Inc., and is a director of Cancerlinq, a big-data digital healthcare platform and wholly owned subsidiary of the American Society of Clinical Oncology (ASCO). Greg holds a Ph.D. in Economics from Northwestern University, an executive leadership program certificate from Harvard Business School, and a dual-major B.A. from University of Rochester (magna cum laude). Greg’s hobbies include gourmet cooking, downhill skiing, and music.

Carlo is an international operations senior executive with global technical, operational, and P&L experience. He has deep expertise in designing and operating global supply chains in complex regulatory environments, leading accretive M&A activity, and devising and executing value-creating strategies in global markets. Since May 2020, Carlo has been the lead advisor for Manufacturing and Supply Chain to Operation Warp Speed/Federal Covid Response, the USG initiative to support acceleration of development and supply of Covid-19 vaccines and therapeutics. He has collaborated with the sponsors, suppliers, and CDMOs to ensure the fast scale-up of manufacturing and distribution for the US. In Carlo’s most recent corporate position, he was Executive VP of Operations at Teva Pharmaceuticals Inc. In this role he was responsible for all Manufacturing, Technology and Capital Investments, Supply Chain, Quality and Compliance, Procurement operations, as well as the global API and CMO business. Carlo retired from this position at the end of 2019. Before joining Teva Pharmaceuticals Inc in 2012, Carlo was the President of Technical Operations and Global Support Functions for Bristol Myers Squibb between 2004 and 2011, where he significantly contributed to the transformation into a focused biopharma company. Carlo received his Doctorate degree in Chemical Engineering and graduated Summa Cum Laude from University of Naples − Naples, Italy.

Paul V. Campanelli was appointed to the Board of Directors for American Injectables, Inc., in March 2024. Additionally, Mr. Campanelli was named as Chairman of the Board for Endo International in November 2019 and previously served as President and Chief Executive Officer from September 2016 until his retirement in March 2020. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endo’s fully integrated Sterile Products and Generics business units, following Endo’s acquisition of Par Pharmaceutical.
Prior to joining Endo, he served as Chief Executive Officer of Par Pharmaceutical
Companies, Inc. following the company’s September 2012 acquisition by TPG. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par
Pharmaceutical, Inc. from 2010 to 2012. At Par Pharmaceutical Inc., Mr. Campanelli had
also served as Executive Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by its board of directors. Prior to joining Par Pharmaceutical Companies, Inc., Mr. Campanelli
served as Vice President, Business Development at Dr. Reddy’s Laboratories Ltd., where he was employed from 1992 to 2001. Currently, Mr. Campanelli is the Executive Chairman of the Board for Pharmaceutical Associates, Inc. He also serves as a Senior Advisor at Bourne Partners. Previously, he served on the boards of directors of Sky Growth Holdings Corporation (Par Pharmaceutical) from 2012 until 2015, Slayback Pharma from 2021 until
2023 and Convey Health from 2022 until 2024. Mr. Campanelli earned his Bachelor of
Science degree from Springfield College.

Akhil Akula is a Vice President at New Rhein Healthcare Investors. Akhil joined the American Injectables Board in March 2024 after working closely with the management team. Prior to joining New Rhein, Akhil worked at Pfizer on the corporate development team. While at Pfizer, Akhil executed several large M&A and licensing transactions and renegotiated existing partnerships. Akhil was also a founding member of the Pfizer Breakthrough Growth Initiatives (“PBGI”), a $500 million vehicle used to invest in early-stage private and public biotech companies. In addition to executing and negotiating PBGI equity investments, he also managed the PBGI portfolio. Previously, Akhil was also an associate at Healthcare Royalty Partners (“HCR”), where he worked on the investment team and supported various activities, including financial analysis, transaction structuring, due diligence, and portfolio management. Before joining HCR, Akhil worked in healthcare investment banking at MTS Health Partners and Ziegler. During his career, Akhil has helped execute over $10 billion of transactions. Akhil graduated from the University of Richmond with a B.S. in Business Administration and a concentration in Finance and completed the pre-medicine curriculum.